The relationship between blood biomarkers and prognosis of pathologic stage IA pure-solid non-small cell lung cancer patients
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Preoperative blood biomarkers like SIRI, NLR, CEA, and SCCA can predict survival in patients with pure-solid non-small cell lung cancer (NSCLC) stage IA after surgery. These markers help identify high-risk patients needing further evaluation.
Area Of Science
- Oncology
- Biomarker Discovery
- Surgical Oncology
Background
- Clinical stage IA non-small cell lung cancer (NSCLC) patients undergoing lobectomy and lymph node dissection may still experience recurrence.
- Pure-solid nodules in NSCLC are associated with higher recurrence rates compared to ground-glass nodules.
- Lack of reliable preoperative biomarkers for identifying high-risk stage IA NSCLC patients necessitates further research.
Purpose Of The Study
- To investigate the prognostic value of preoperative blood biomarkers in patients with pathological stage IA (pIA) pure-solid NSCLC.
- To identify reliable biomarkers for predicting recurrence and survival in pIA NSCLC patients post-surgery.
Main Methods
- Retrospective review of 255 NSCLC patients (205 pIA, 50 pT1N1-2M0) who underwent radical surgery (2014-2016).
- Receiver operating characteristic (ROC) analysis to determine optimal biomarker cut-off values.
- Kaplan-Meier method and Cox regression analyses to assess predictors of disease-free survival (DFS) and overall survival (OS).
Main Results
- Neutrophil to lymphocyte ratio (NLR) and serum carcinoembryonic antigen (CEA) were independent predictors of DFS in pIA NSCLC.
- Systemic inflammatory response index (SIRI), CEA, and serum squamous cell carcinoma antigen (SCCA) were independent predictors of OS in pIA NSCLC.
- Elevated SIRI and CEA levels correlated with survival rates similar to those in the pN1 lymph node metastasis group.
Conclusions
- Preoperative SIRI, NLR, CEA, and SCCA show potential as prognostic biomarkers for pIA pure-solid NSCLC patients.
- These biomarkers may aid in stratifying patients and guiding adjuvant therapy decisions.
- Further validation is needed to confirm the clinical utility of these blood markers.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...